Grifols has filed a patent for methods using CCR3 modulating agents to improve visual endpoints in retina-associated diseases like retinopathy of prematurity and age-related macular degeneration. The claim details have been canceled. GlobalData’s report on Grifols gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Grifols, Attenuated virus-based vaccines was a key innovation area identified from patents. Grifols's grant share as of January 2024 was 51%. Grant share is based on the ratio of number of grants to total number of patents.
Improving visual endpoints related to retina-associated diseases
See Also:
A recently filed patent (Publication Number: US20240024305A1) outlines a method for improving visual acuity in individuals diagnosed with retina-associated diseases. The method involves orally administering a compound of Formula 2 to the subject in a therapeutically effective amount. The compound's specific structural characteristics, including the configuration of R1, R2a, R2b, and other substituents, are detailed in the patent claims to ensure optimal efficacy in treating the targeted conditions.
Furthermore, the patent describes various formulations and compositions of the compound, including crystalline salts and pharmaceutical compositions with buffering agents and basic amino acids. The method also allows for the administration of the compound in different forms such as capsules, tablets, or film-coated tablets, with specific details on the film coat composition. Additionally, the patent suggests combining the compound with anti-VEGF therapy for enhanced treatment outcomes in a range of retina-associated diseases like age-related macular degeneration and retinopathy. Overall, the patent provides a comprehensive guide for utilizing the compound of Formula 2 to address visual acuity issues associated with various retinal conditions, offering potential advancements in the field of ophthalmology.
To know more about GlobalData’s detailed insights on Grifols, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
